Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Vous n'êtes pas connecté
Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to...
Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function,...